NASDAQ:DCPH - Nasdaq - US24344T1016 - Common Stock - Currency: USD
DCPH gets a fundamental rating of 4 out of 10. The analysis compared the fundamentals against 556 industry peers in the Biotechnology industry. No worries on liquidiy or solvency for DCPH as it has an excellent financial health rating, but there are worries on the profitability. While showing a medium growth rate, DCPH is valued expensive at the moment.
Industry Rank | Sector Rank | ||
---|---|---|---|
ROA | -45.24% | ||
ROE | -60.25% | ||
ROIC | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
OM | N/A | ||
PM (TTM) | N/A | ||
GM | 96.95% |
Industry Rank | Sector Rank | ||
---|---|---|---|
Debt/Equity | 0 | ||
Debt/FCF | N/A | ||
Altman-Z | 7.32 |
Industry Rank | Sector Rank | ||
---|---|---|---|
Current Ratio | 4.19 | ||
Quick Ratio | 3.94 |
Industry Rank | Sector Rank | ||
---|---|---|---|
PE | N/A | ||
Fwd PE | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
P/FCF | N/A | ||
EV/EBITDA | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
Dividend Yield | N/A |
25.59
+0.02 (+0.08%)
Industry Rank | Sector Rank | ||
---|---|---|---|
Dividend Yield | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
PE | N/A | ||
Fwd PE | N/A | ||
P/S | 12.65 | ||
P/FCF | N/A | ||
P/OCF | N/A | ||
P/B | 7 | ||
P/tB | 7 | ||
EV/EBITDA | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
ROA | -45.24% | ||
ROE | -60.25% | ||
ROCE | N/A | ||
ROIC | N/A | ||
ROICexc | N/A | ||
ROICexgc | N/A | ||
OM | N/A | ||
PM (TTM) | N/A | ||
GM | 96.95% | ||
FCFM | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
Debt/Equity | 0 | ||
Debt/FCF | N/A | ||
Debt/EBITDA | N/A | ||
Cap/Depr | 29.04% | ||
Cap/Sales | 0.32% | ||
Interest Coverage | N/A | ||
Cash Conversion | N/A | ||
Profit Quality | N/A | ||
Current Ratio | 4.19 | ||
Quick Ratio | 3.94 | ||
Altman-Z | 7.32 |